Decreased serum levels of brain-derived neurotrophic factor in schizophrenic patients with deficit syndrome

Akyol, Esra Soydaş; Albayrak, Yakup; Beyazyüz, Murat; Aksoy, Nurkan; Kuloğlu, Murat; Hashimoto, Kenji

doi:10.2147/ndt.s79444

Cited by 10 publications

(10 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 47 We recently showed significantly decreased BDNF levels in patients with DS when compared with HC. 48 Thus, our two previous studies indirectly supported the hypothesis of an increased apoptotic mechanism in DS patients. In the present study, we demonstrated increased levels of apoptosis in patients with DS when compared with the NDS and HC groups.…”

Section: Discussionsupporting

confidence: 73%

Increased serum levels of apoptosis in deficit syndrome schizophrenia patients: a preliminary study

Beyazyüz¹,

Kufeciler²,

Bulut³

et al. 2016

NDT

Self Cite

View full text Add to dashboard Cite

BackgroundSchizophrenia is a chronic and debilitating disorder, the etiology of which remains unclear. Apoptosis is a programmed cell death mechanism that might be implicated in neuropsychiatric disorders, including schizophrenia. In this study, we aimed to compare the serum levels of apoptosis among deficit schizophrenia (DS) syndrome patients, nondeficit schizophrenia (NDS) patients, and healthy controls (HCs).Patients and methodsAfter the inclusion and exclusion criteria were applied, 23 DS patients, 46 NDS patients, and 33 HCs were included in the study. The serum apoptosis levels were measured using a quantitative sandwich enzyme immunoassay with human monoclonal antibodies directed against DNA and histones.ResultsThere was a significant difference among the three groups in terms of the levels of apoptosis (F2,96=16.58; P<0.001). The serum apoptosis levels in the DS and NDS groups were significantly higher than those in the HC group. Furthermore, the serum apoptosis levels in the DS group were significantly higher than the levels in the NDS group.ConclusionThis study suggests that increased levels of apoptosis may be implicated in the pathophysiology of DS syndrome. However, further studies are needed to support the role of apoptosis in DS.

show abstract

Section: Discussionsupporting

confidence: 73%

Increased serum levels of apoptosis in deficit syndrome schizophrenia patients: a preliminary study

Beyazyüz¹,

Kufeciler²,

Bulut³

et al. 2016

NDT

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, clinical investigations of BDNF in psychiatric disorders is contradictory. Some reports have stated reduced blood BDNF levels in patients with SCZ ( Yang et al, 2011 ; Akyol et al, 2015 ; XY Zhang et al, 2015 ), BD ( Machado-Vieira et al, 2007 ; de Oliveira et al, 2009 ), and MDD ( Sen et al, 2008 ; Bocchio-Chiavetto et al, 2010 ; Polyakova et al, 2015 ), whereas others have confirmed opposite findings ( Durany et al, 2001 ; Jevtović et al, 2011 ; Munkholm et al, 2014 ). Nevertheless, some meta-analysis of case-control studies examined changes in BDNF following pharmacologic treatment in psychiatric disorders ( Goldstein and Young, 2013 ; Pagsberg et al, 2014 ; Yan et al, 2014 ).…”

Section: Biomarker Discovery Researchmentioning

confidence: 98%

“…A number of preclinical studies have also suggested that the brain-derived neurotrophic factor (BDNF), a well-established neurotrophin, plays an important role in the pathophysiology of numerous psychiatric disorders ( Teche et al, 2013 ; Munkholm et al, 2014 ; Akyol et al, 2015 ) and regulates neuronal growth, survival, and function of the adult brain ( Yukimasa et al, 2006 ; Calabrese et al, 2014 ). However, clinical investigations of BDNF in psychiatric disorders is contradictory.…”

Section: Biomarker Discovery Researchmentioning

confidence: 99%

Omics-Based Biomarkers: Application of Metabolomics in Neuropsychiatric Disorders

Sethi

Brietzke

2015

IJNPPY

View full text Add to dashboard Cite

One of the major concerns of modern society is to identify putative biomarkers that serve as a valuable early diagnostic tool to identify a subset of patients with increased risk to develop neuropsychiatric disorders. Biomarker identification in neuropsychiatric disorders is proposed to offer a number of important benefits to patient well-being, including prediction of forthcoming disease, diagnostic precision, and a level of disease description that would guide treatment choice. Nowadays, the metabolomics approach has unlocked new possibilities in diagnostics of devastating disorders like neuropsychiatric disorders. Metabolomics-based technologies have the potential to map early biochemical changes in disease and hence provide an opportunity to develop predictive biomarkers that can be used as indicators of pathological abnormalities prior to development of clinical symptoms of neuropsychiatric disorders. This review highlights different -omics strategies for biomarker discovery in neuropsychiatric disorders. We also highlight initial outcomes from metabolomics studies in psychiatric disorders such as schizophrenia, bipolar disorder, and addictive disorders. This review will also present issues and challenges regarding the implementation of the metabolomics approach as a routine diagnostic tool in the clinical laboratory in context with neuropsychiatric disorders.

show abstract

“…There is mounting evidences that DS may be a distinct subtype of schizophrenia, which may help to reduce the heterogeneity of this disease. Akyol et al reported that the serum BDNF levels in DS were significantly lower than those in the healthy individuals, while those in NDS patients were similar to normal levels [19]. In contrast, Valiente-Gómez et al did not find any significant differences across the three groups [20].…”

Section: Introductionmentioning

confidence: 99%

Serum BDNF and GDNF in Chinese male patients with deficit schizophrenia and their relationships with neurocognitive dysfunction

et al. 2019

View full text Add to dashboard Cite

Background To measure the serum levels of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) in deficit schizophrenia (DS), in order to examine the association between these two neurotrophic factors (NFs) and cognitive performance. Methods A total of 109 male patients [51 DS and 58 non-deficit schizophrenia (NDS)] with schizophrenia and 40 sex and age matched healthy controls (HC) participated in this study. Processing speed, attention, executive function, and working memory of all subjects were assessed by means of a battery of classical neuropsychological tests. Serum BDNF and GDNF levels were measured simultaneously using a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA). Results There were significant differences in the overall cognitive test scores between three groups (all p < 0.001). Serum BDNF levels were significantly lower in patients (DS and NDS) than in HC ( p < 0.001). Furthermore, BDNF levels were lower in the DS compared to the NDS group, although not significantly. However, there was no difference in the GDNF levels between patients (DS and NDS) and HC. GDNF levels were positively correlated with scores of Stroop words only ( r = 0.311, p = 0.033), Stroop colors only ( r = 0.356, p = 0.014) and Stroop interference ( r = 0.348, p = 0.016) in DS group . Conclusion Serum BDNF may be an unsuitable biomarker for DS, despite a significant decrease in schizophrenia patients. The different neurocognitive performance between the DS and NDS patients indicates that DS may be a separate clinical entity of schizophrenia. Finally, higher serum GDNF levels are associated with better cognitive performance in DS patients, indicating a possible neuroprotective function in DS.

show abstract

Decreased serum levels of brain-derived neurotrophic factor in schizophrenic patients with deficit syndrome

Cited by 10 publications

References 59 publications

Increased serum levels of apoptosis in deficit syndrome schizophrenia patients: a preliminary study

Increased serum levels of apoptosis in deficit syndrome schizophrenia patients: a preliminary study

Omics-Based Biomarkers: Application of Metabolomics in Neuropsychiatric Disorders

Serum BDNF and GDNF in Chinese male patients with deficit schizophrenia and their relationships with neurocognitive dysfunction

Contact Info

Product

Resources

About